Zimbabwe Receives 2000 Doses of Injectable PrEP
Zimbabwe is the third African nation to introduce injectable cabotegravir (CAB-LA) following Malawi and Zambia
Zimbabwe Receives 2000 Doses of Injectable PrEP
In a significant stride towards enhancing HIV prevention strategies, Population Solutions for Health recently marked a milestone as the first recipient of care for the revolutionary injectable cabotegravir (CAB-LA) at Harare’s New Start Centre.
This groundbreaking biomedical HIV prevention method, now available as pre-exposure prophylaxis (PrEP), is poised to transform the landscape of HIV transmission prevention among high-risk populations.
Injectable PrEP has emerged as a beacon of hope in the global endeavor to eliminate HIV/AIDS as a public health threat by 2030.
Zimbabwe, standing at the forefront of progressive healthcare initiatives, has become the third African nation to introduce injectable cabotegravir (CAB-LA) following Malawi and Zambia.
Zimbabwe Receives 2000 Doses of Injectable PrEP
This strategic move promises to broaden the spectrum of HIV prevention options accessible to Zimbabweans, reinforcing the nation’s commitment to combating the HIV epidemic.
The administration of injectable cabotegravir for HIV PrEP is facilitated by healthcare professionals, ensuring precise and effective delivery of this cutting-edge preventive measure.
The treatment protocol involves an initial intramuscular (IM) injection of cabotegravir once a month for the first two months, followed by subsequent IM injections once every two months thereafter.
This development underscores not only the technological advancements in HIV prevention but also the collaborative efforts of healthcare organizations and governmental bodies in promoting public health initiatives.
As Zimbabwe embraces this innovative PrEP solution, it paves the way for improved health outcomes and a brighter future in the ongoing battle against HIV/AIDS.
